152 related articles for article (PubMed ID: 7680277)
1. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume.
Schmid HP; McNeal JE; Stamey TA
Cancer; 1993 Mar; 71(6):2031-40. PubMed ID: 7680277
[TBL] [Abstract][Full Text] [Related]
2. Clinical observations on the doubling time of prostate cancer.
Schmid HP; McNeal JE; Stamey TA
Eur Urol; 1993; 23 Suppl 2():60-3. PubMed ID: 7685704
[TBL] [Abstract][Full Text] [Related]
3. Tumour markers in patients on deferred treatment: prostate specific antigen doubling times.
Schmid HP
Cancer Surv; 1995; 23():157-67. PubMed ID: 7542562
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer.
Zagars GK; Pollack A
Radiother Oncol; 1997 Sep; 44(3):213-21. PubMed ID: 9380819
[TBL] [Abstract][Full Text] [Related]
5. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
6. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
7. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer.
Zagars GK; Pollack A
Cancer; 1993 Aug; 72(3):832-42. PubMed ID: 7687516
[TBL] [Abstract][Full Text] [Related]
8. Natural history of changes in prostate specific antigen in early stage prostate cancer.
Pearson JD; Carter HB
J Urol; 1994 Nov; 152(5 Pt 2):1743-8. PubMed ID: 7523722
[TBL] [Abstract][Full Text] [Related]
9. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
Stephan C; Lein M; Jung K; Schnorr D; Loening SA
Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
[TBL] [Abstract][Full Text] [Related]
11. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
Coakley FV; Chen I; Qayyum A; Westphalen AC; Carroll PR; Hricak H; Chen MH; Kurhanewicz J
BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
[TBL] [Abstract][Full Text] [Related]
12. Serial prostate specific antigen measurements and progression in untreated confined (stages T0 to 3NxM0, grades 1 to 3) carcinoma of the prostate.
Bangma CH; HOP WCJ ; Schröder FH
J Urol; 1995 Oct; 154(4):1403-6. PubMed ID: 7544841
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
Andriole GL; Marberger M; Roehrborn CG
J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
[TBL] [Abstract][Full Text] [Related]
14. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease.
Carter HB; Morrell CH; Pearson JD; Brant LJ; Plato CC; Metter EJ; Chan DW; Fozard JL; Walsh PC
Cancer Res; 1992 Jun; 52(12):3323-8. PubMed ID: 1375867
[TBL] [Abstract][Full Text] [Related]
15. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
[TBL] [Abstract][Full Text] [Related]
16. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
17. [Circulating prostatic-specific antigen in benign hypertrophy and localized prostate cancer: can PSA be considered a screening examination for localized cancer?].
Perrin P; Francois O; Maquet JH; Bringeon G; Duteil P; Devonec M
Prog Urol; 1991 Jun; 1(3):419-31. PubMed ID: 1726943
[TBL] [Abstract][Full Text] [Related]
18. Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma.
Egawa S; Matsumoto K; Suyama K; Iwamura M; Kuwao S; Baba S
Cancer; 1999 Aug; 86(3):463-9. PubMed ID: 10430254
[TBL] [Abstract][Full Text] [Related]
19. Serum prostate-specific antigen and the biologic progression of prostate cancer.
Kabalin JN; McNeal JE; Johnstone IM; Stamey TA
Urology; 1995 Jul; 46(1):65-70. PubMed ID: 7541589
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy.
Gerber GS; Gornik HL; Goldfischer ER; Chodak GW; Rukstalis DB
J Urol; 1998 Apr; 159(4):1243-6. PubMed ID: 9507845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
